TTM
$28.9B
YoY change
+15.5%
5Y CAGR
+20.8%
Peak year (FY2025)
$24.4B
Cumulative EBITDA
$183B
EBITDA history chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: $24.4B
EBITDA growth chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: +15.5%
EBITDA history table for Novo Nordisk (NVO) from 2003 to 2025
| FY2025 | $24.4B | +15.5% | +$3.27B | ||
| FY2024 | $21.2B | +27.9% | +$4.61B | ||
| FY2023 | $16.5B | +56.8% | +$5.99B | ||
| FY2022 | $10.6B | +5.0% | +$500M | ||
| FY2021 | $10.1B | +5.8% | +$553M | ||
| FY2020 | $9.5B | +17.8% | +$1.43B | ||
| FY2019 | $8.07B | +2.2% | +$175M | ||
| FY2018 | $7.89B | -4.0% | -$328M | ||
| FY2017 | $8.22B | +11.1% | +$823M | ||
| FY2016 | $7.4B | +8.4% | +$571M | ||
| FY2015 | $6.83B | +8.3% | +$523M | ||
| FY2014 | $6.3B | -2.4% | -$156M | ||
| FY2013 | $6.46B | +21.5% | +$1.14B | ||
| FY2012 | $5.32B | +17.7% | +$801M | ||
| FY2011 | $4.52B | +16.7% | +$645M | ||
| FY2010 | $3.87B | +9.6% | +$339M | ||
| FY2009 | $3.53B | +34.2% | +$900M | ||
| FY2008 | $2.63B | +13.2% | +$307M | ||
| FY2007 | $2.33B | +19.4% | +$377M | ||
| FY2006 | $1.95B | +22.2% | +$353M | ||
| FY2005 | $1.6B | +2.2% | +$34.2M | ||
| FY2004 | $1.56B | +17.6% | +$233M | ||
| FY2003 | $1.33B | — | — | ||
| FY2002 | — | — | — | ||
| FY2001 | — | — | — | ||
| FY2000 | — | — | — | ||
| FY1999 | — | — | — | ||
| FY1998 | — | — | — | ||
| FY1997 | — | — | — | ||
| FY1996 | — | — | — | ||
| FY1995 | — | — | — | ||
| FY1994 | — | — | — | ||
| FY1993 | — | — | — | ||
| FY1992 | — | — | — | ||
| FY1991 | — | — | — | ||
| FY1990 | — | — | — | ||
| FY1989 | — | — | — | ||
| FY1988 | — | — | — | ||
| FY1987 | — | — | — | ||
| FY1986 | — | — | — | ||
| FY1985 | — | — | — |
- FY2025$24.4B+15.5%
- FY2024$21.2B+27.9%
- FY2023$16.5B+56.8%
- FY2022$10.6B+5.0%
- FY2021$10.1B+5.8%
- FY2020$9.5B+17.8%
- FY2019$8.07B+2.2%
- FY2018$7.89B-4.0%
- FY2017$8.22B+11.1%
- FY2016$7.4B+8.4%
- FY2015$6.83B+8.3%
- FY2014$6.3B-2.4%
- FY2013$6.46B+21.5%
- FY2012$5.32B+17.7%
- FY2011$4.52B+16.7%
- FY2010$3.87B+9.6%
- FY2009$3.53B+34.2%
- FY2008$2.63B+13.2%
- FY2007$2.33B+19.4%
- FY2006$1.95B+22.2%
- FY2005$1.6B+2.2%
- FY2004$1.56B+17.6%
- FY2003$1.33B—
- FY2002——
- FY2001——
- FY2000——
- FY1999——
- FY1998——
- FY1997——
- FY1996——
- FY1995——
- FY1994——
- FY1993——
- FY1992——
- FY1991——
- FY1990——
- FY1989——
- FY1988——
- FY1987——
- FY1986——
- FY1985——
EBITDA values are taken from Novo Nordisk's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About EBITDA at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's current EBITDA (TTM) is $28.9B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Novo Nordisk (NVO) reported EBITDA of 157B DKK – grew 5.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Novo Nordisk EBITDA compounded at +21.5% per year, sustaining 7 straight years of year-over-year growth.
The record annual EBITDA stands at 157B DKK, reached in 2025; the historical low of 894M DKK was recorded in 1986.
Novo Nordisk EBITDA by Year
Novo Nordisk EBITDA 2025: $24.4B
Novo Nordisk posted EBITDA of 157B DKK ($24.4B) in 2025, grew 5.9% from 2024. This figure represents the highest annual value in the available history.
Novo Nordisk EBITDA 2024: $21.2B
In 2024, Novo Nordisk reported EBITDA of 148B DKK ($21.2B), grew 29.1% from 2023.
Novo Nordisk EBITDA 2023: $16.5B
Novo Nordisk EBITDA in 2023 was 115B DKK ($16.5B), surged 49.3% from 2022.
Novo Nordisk EBITDA 2022: $10.6B
2022's EBITDA for Novo Nordisk came in at 76.8B DKK ($10.6B), grew 17.4% from 2021.
Novo Nordisk EBITDA 2021: $10.1B
Novo Nordisk EBITDA in 2021 was 65.4B DKK ($10.1B).
See more financial history for Novo Nordisk (NVO).
Sector peers by EBITDA
Healthcare peers of Novo Nordisk (NVO), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $23.1B | |
| $17.6B | |
| $16.9B | |
| $11.6B | |
| $11.5B |
- $41.1B
- $28.3B
- $27.9B
- $23.1B
- $17.6B
- $16.9B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.23% TTM
- Dividend Profile3.49% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.